A physician with a longstanding interest in gene therapy, Dr. High was formerly a Professor at the Perelman School of Medicine of the University of Pennsylvania, an Investigator of the Howard Hughes Medical Institute, and the Founding Director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, a Center focused on developing
novel cell and gene - based therapies for genetic disease.
Dr. Levine directs the Clinical Cell and Vaccine Production Facility (CVPF), which develops, manufactures, and tests
novel cell and gene therapies in clinical trials at Penn and collaborating institutions.
Not exact matches
M. J. Bertram et al., Identification of a
gene that reverses the immortal phenotype of a subset of
cells and is a member of a
novel family of transcription factor - like
genes.
Novel abnormalities in the FGFR
gene, called FGFR fusions, were identified in a spectrum of cancers,
and preliminary results with cancer
cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
«Our research has identified a
gene affecting another type of ischemic stroke, due to small vessel disease,
and also suggests some
genes may be associated with both ischemic
and hemorrhagic stroke
and may act through a
novel pathway affecting pericytes, a type of
cell in the wall of small arteries
and capillaries.
Monsanto's newest drought - tolerant product, Drought Guard, relies on a
gene that creates a chaperone protein to coat a plant's RNA during stressful conditions
and maintain the plant's normal
cell functions, while Syngenta's hybrid contains
novel drought - tolerant
gene combinations.
By identifying
novel genes and molecular pathways involved in shaping a taste
cell's function, these findings may someday allow scientists to treat taste disorders, characterize new taste qualities, or even fine - tune a person's taste perception to encourage healthier eating.
Using
novel technologies developed at HMS, the team looked at how a single sensory experience affects
gene expression in the brain by analyzing more than 114,000 individual
cells in the mouse visual cortex before
and after exposure to light.
«In addition to known disease - related
genes, we have discovered seven
novel genes as the cause of X-linked intellectual disability
and analysed what signaling pathways in the
cells each protein is involved in,» says Kalscheuer.
Inflammation response induces the transcription of the Irg1
gene and enhancer RNAs, causing the emergence of
novel enhancer regions
and a
novel enhancer landscape within a
cell.
Given his training in developmental biology, Raman focused the team to seek a
novel drug target on
genes important to the development of model organisms — fruit flies (Drosophila)
and yeast (Saccharomyces cerevisiae)-- rather than on oncogenes that transform a normal
cell into a cancer
cell.
The group took the first step toward their goal of a
novel engineering strategy for yeast by creating what is known as a cDNA library: a collection of over 90 % of the
genes from the genome of baker's yeast (Saccharomyces cerevisiae), arranged within a custom segment of DNA so that each
gene will be, in one version, overactive within a yeast
cell,
and in a second version, reduced in activity.
However, coreceptor - specific ZFNs represent a
novel therapeutic approach to recapitulate this success via autologous transplantation of
gene - modified hematopoietic stem
cells and mature CD4 + T
cells.
Use of exon - based transcriptome profiling to identify
novel signaling pathways
and survival - associated
genes in diffuse large B -
cell lymphoma.
Using a
novel technique to genetically modify T
cells for adoptive transfer, Carl June, Michael Kalos, David Porter, Bruce Levine,
and colleagues at the University of Pennsylvania School of Medicine achieve clinical responses in patients with chronic lymphocytic leukemia, including two complete, durable (one year) clinical responses, accompanied by in vivo expansion
and long - term functional persistence of
gene - modified
cells.
Using a
novel methodology, the researchers found an association between the disorder
and a DNA marker that is very close to the dopamine transporter
gene, which controls the intake of this important neural messenger by the nerve
cells that respond to dopamine's signal.
We are focusing on a few key molecular pathways including; 1) Polycomb - mediated epigenetic
gene silencing in the tumor initiation, maintenance,
and invasion, 2) c - Met (receptor tyrosine kinase) signal transduction pathways in stemness
and migration of these tumor
cells, 3)
Novel mitogenic signaling pathways that are specific to GSCs,
and 4) Identification of radio -
and chemo - sensitizing pathway to maximize therapeutic efficacy.
A
novel way of approaching protection - based therapeutics for glaucoma should derive from evidence accumulating over two decades in stroke
and cardiac arrest: That simultaneously activating a variety of self - defense responses in
cells with stressful «conditioning» stimuli induces the expression of a host of
genes that promote
cell survival.
Collaborating with the labs of Salk Professors Joseph Ecker
and Alan Saghatelian, the Izpisua Belmonte team performed extensive characterization of the new
cells and found rsPSCs showed distinct molecular
and metabolic characteristics as well as
novel epigenetic signatures — that is, patterns of chemical modifications to DNA that control which
genes are turned on or off without changing the DNA sequence.
We identified
and characterized a
novel member of the forkhead
gene family that is essential for proper regulation of satellite
cells.
BRD7, a
novel PBAF - specific SWI / SNF subunit, is required for target
gene activation
and repression in embryonic stem
cells.
We will use these data to characterize
novel genes that regulate the quiescent
and proliferative states of β -
cells.
The researchers particularly identified three
novel candidate
genes; KIRREL3
and SLIT1, with documented roles in immune
cell development,
and SERPINA9 expressed exclusively at the site (germinal center) where a B -
cell starts producing IgA.
The next step based on these
novel head
and neck cancer discoveries, the scientists agree, is to tease out how the
genes function in normal
cells, whether they form the lining of the larynx, pharynx, or another anatomical site affected by head
and neck cancer.
Dissertation work led to phenotypic validation of a
novel gene for the scale - up
and expansion of stem
cells.
He is the principal discoverer of the p21 activated protein kinase (PAK) family of
cell signalling proteins
and of
novel virulence - inducing
genes in pathogenic fungi.
Using a combination of stem
cells and novel analytical tools, scientists at the Wellcome Sanger Institute
and their collaborators discovered that clues to the contribution of genetic variation to disease risk lie not only in the
genes, but also in the molecular switches that control those
genes.
Graber will also lead the development of the Comparative Models of Regeneration Database (RegenDB), a
novel bioinformatics resource supported by the National Institutes of Health (NIH) whose function is to integrate
gene function across multiple animal, tissue
and cell models in order to validate
and inform the hypotheses needed for the discovery
and development of regenerative medicine drug therapies.
Dr. Bulte oversees the development of
novel reporter
genes that can provide contrast on MRI scans,
and artificial proteins in mammalian
cells that contain specific proton exchangable groups of which the proton signal can be manipulated.
Gene and cell therapies have made important medical advances over the past three decade, developing technologies
and testing
novel therapies in multiple human clinical trials of many diseases.
Mapping the epigenome will allow Vijay
and his team to zoom in on those
genes with the greatest likelihood to contribute to disease,
and the
cell types in which they act,
and therefore will help identify
novel therapeutic targets.
We have discovered multiple
genes critical for generating liver
and pancreas
cells and have created
novel animal models for diseases such as diabetes
and Alagille Syndrome.
Cenix BioScience is a contract research organization focused on the discovery
and pre-clinical development of
novel therapeutics, specializing in advanced applications of RNA interference (RNAi)
gene silencing combined with high content phenotyping in cultured
cells in vitro
and in animals in vivo.
The scientific goal of the Cancer Biology Program is to identify
novel genomic
and genetic alterations that play causal roles in cancer development
and to study
genes, proteins,
and signaling pathways that mediate the altered phenotypes of cancer
cells.
Analyzing patterns of
gene expression in individual human immune system
cells, the researchers refined the definitions of the types known as dendritic
cells and monocytes
and identified a
novel type that had been overlooked.
The Kind group studies the regulation of
gene expression in single
cells by developing
and using
novel microscopy
and genomics based techniques.
«Our study also highlights that growth of normal
cells and cancer
cells is driven by different
gene switches, suggesting that further work to find ways to control the activity of such disease - specific switches could lead to
novel, highly specific approaches for therapeutic intervention», says Professor Jussi Taipale, who led the study.
Talks will discuss the origination of
novel cell type
gene regulatory networks,
and cover the latest research into the evolution of
cell type functional modules, such as protein complexes
and larger macromolecular structures.
We propose that
genes involved in
cell migration
and invasion, such as fascin1, could serve as
novel targets for metastasis prevention.
NYSCF — Robertson Stem
Cell Investigator
and NYSCF — Robertson Stem
Cell Prize recipient Feng Zhang, PhD, Core Member of the Broad Institute of Harvard
and MIT, shared yet another
novel update of CRISPR
gene editing technology.
To uncover molecular processes in individual
cells and to understand the full complexity of biological systems, our lab applies
and develops
novel microscopy
and genomics based techniques to study the regulation of
gene - expression in single
cells.
We use the Haplobank in reverse genetic screens to investigate the temporal resolution of essential
genes in mES
cells,
and to identify
novel genes that control sprouting angiogenesis
and lineage specification of blood vessels.
Senoo M, Tsuchiya I, Matsumura Y, Mori T, Saito Y, Kato H, Okamoto T, Habu S. Transcriptional dysregulation of the p73L / p63 / p51 / p40 / KET
gene in human squamous
cell carcinomas: expression of Delta Np73L, a
novel dominant - negative isoform,
and loss of expression of the potential tumour suppressor p51.
309/5: 00 Meta - analysis of rare
and common exome chip variants identifies
and replicates S1PR4
and other
novel genes influencing blood
cell traits.
Microarray studies have the potential to piece together groups of co-regulated
genes and thus lead to the discovery of
novel components of genetic pathways in ES
cells.
Clinical
and Regenerative medicine refers to development
and implementation of advanced therapeutic approaches that may involve the support of expertise in
gene /
cell therapy, tissue engineering, pharmacology
and pharmacogenomics, development of
novel molecular target therapy.